“Biogen’s $6.5 Billion Acquisition of Reata Strengthens Rare Disease Portfolio”
“Biogen’s $6.5 Billion Acquisition of Reata Pharmaceuticals Marks a Milestone for Rare Disease Treatments” July 28 – Biogen (BIIB.O), a renowned biotechnology firm, has made a groundbreaking move to acquire rare disease drugmaker Reata Pharmaceuticals (RETA.O) for an impressive $6.5 billion. This strategic acquisition, led by new CEO Christopher Viehbacher, aims to propel Biogen towards … Read more